Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 10/20 | 1.00 |
| ▸ | RARA | P10276 | 4/20 | 1.00 |
| ▸ | RARG | P13631 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370734 | 1.00 | RARB (1.00) | RARBRARARARGMEN1MAPT | |
| SCHEMBL23016677 | 0.88 | RARB (0.78) | RARBRARARARGMAPTHRH3 | |
| SCHEMBL4188775 | 0.86 | RARB (1.00) | RARBRARARARGHRH3 | |
| SCHEMBL17322460 | 0.85 | RARB (0.74) | RARBRARARARGFFAR4HRH3 | |
| SCHEMBL22080976 | 0.80 | RARB (0.66) | RARBRARARARGPPARDPPARA | |
| SCHEMBL4190212 | 0.79 | RARB (1.00) | RARBRARARARGMEN1MAPT | |
| SCHEMBL23280818 | 0.79 | RARB (0.66) | RARBRARARARGMEN1MAPT | |
| SCHEMBL4190534 | 0.78 | RARB (1.00) | RARBRARARARGMCL1 | |
| SCHEMBL4597544 | 0.77 | RARB (0.98) | RARBRARARARGMEN1MAPT | |
| SCHEMBL4190297 | 0.75 | RARB (0.83) | RARBRARARARGMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016148-A1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS TO ATTENUATE ANTHRACYCLINE-INDUCED CARDIOTOXICITY | NORTHWESTERN UNIVERSITY | 2022-01-20 | — | — | US | claimed |
| US-10668039-B2 | Methods for treatment of adenoid cystic carcinoma | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-06-02 | — | — | US | claimed |
| US-20190192468-A1 | METHODS FOR TREATMENT OF ADENOID CYSTIC CARCINOMA | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2019-06-27 | — | — | US | claimed |
| WO-2018045289-A1 | METHODS FOR TREATMENT OF ADENOID CYSTIC CARCINOMA | ZON LEONARD I (US) | 2018-03-08 | — | — | WO | claimed |
| US-12529032-B2 | Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250345316-A1 | METHODS OF INCREASING LYMPHOCYTE TRAFFICKING TO THE COLON BY STIMULATING RETINOIC ACID RECEPTORS AND ARYL HYDROCARBON RECEPTORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-13 | — | — | US | disclosed |
| US-20240392241-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2024171957-A1 | TRANSPLANTATION OF PITUITARY HORMONE-PRODUCING CELLS | 国立大学法人東海国立大学機構 | 2024-08-22 | — | — | WO | disclosed |
| EP-4410963-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | Sumitomo Chemical Company, Limited (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-118318033-A | Cell aggregate comprising pituitary hormone-producing cells and method for producing the same | 住友制药株式会社 | 2024-07-09 | — | — | CN | disclosed |
| CN-118043447-A | Method for preparing cell population containing pituitary tissue and cell population | 住友化学株式会社 | 2024-05-14 | — | — | CN | disclosed |
| CN-118021814-A | Combination therapy with EHMT2 inhibitors | EPIZYME股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20140329903-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140187504-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREREGIMMUNE, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187504-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREREGIMMUNE, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | SONY CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | SONY CORPORATION (JP) | 2009-07-09 | — | — | US | disclosed |
| EP-1907347-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | Arcadia Pharmaceuticals Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009083-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007009083-A2 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12529032-B2 | Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures | NES, CDH1, SHH | RARB 24/4885RARA 57/4885RARG 54/4885 |
| US-20140187504-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | FABP1, RARA, RXRA | RARB 5/4885RARA 2/4885RARG 4/4885 |
| US-20140329903-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PSEN2, NLN | RARB 2204/4885RARA 3457/4885RARG 2756/4885 |
| US-20220016148-A1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS TO ATTENUATE ANTHRACYCLINE-INDUCED CARDIOTOXICITY | RARG, RXRG, RARA | RARB 4/4885RARA 3/4885RARG 1/4885 |
| US-20090176837-A1 | COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS | RARB, RARA, RARG | RARB 1/4885RARA 2/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.